ArticleArchives of medical science : AMS2012
α-Glucosidase inhibitors and their use in clinical practice.
Article in Archives of medical science : AMS, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 1 synthesis or guideline pooled it, 407 citations in OpenAlex.
- Intervening Early in the Cardiovascular-Kidney-Metabolic Syndrome: Expert Recommendations from the United Arab Emirates on the Management of Prediabetes.Vascular health and risk management · 2026Guideline
- Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.Diabetes & metabolism journal · 2019Trial
- Postprandial Blood Glucose Lowering Effect of Urtica cannabina L. and Its Chemical Profiling via UPLC-Triple-TOF MS/MS.Journal of food science · 2026Article
- Novel sulfonylhydrazide anacardic acid derivatives as potent α-glucosidase inhibitors: Synthesis, crystal structure, biological evaluation, and computational studies.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- In Vitro Inhibition of Digestive Enzymes by Leaf Metabolites fromMolecules (Basel, Switzerland) · 2026Article
- Structural Modifications of Hybrid O-Alkylsulfonyl-β-(Benzimidazol-1-yl)propioamidoximes as a Pathway to the Antimicrobial, Antifungal and Antidiabetic Drugs.International journal of molecular sciences · 2026Article
- UPLC-MS/MS analysis and bioactivity comparison of wild and cultivatedRSC advances · 2026Article
- Evaluation of the tolerance and effects of 1-deoxynojirimycin on insulin and glucose dynamics in healthy horses and horses at risk for insulin dysregulation.Journal of veterinary internal medicine · 2026Article
- Therapeutic impacts of oral anti-diabetic drugs on Inflammatory Bowel Disease (IBD), a comprehensive review of clinical and preclinical studies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- The Emergence of Bioactive Peptides as Anti-diabetic Agents: A Review.Current protein & peptide science · 2026Review
- Article
- An integrative computational strategy for antidiabetic drug discovery: From QSAR modeling to retrosynthesis.BioImpacts : BI · 2026Article
- Mechanistic study of α-mangostin derivatives as potent α-glucosidase inhibitors.Molecular diversity · 2025Article
- Profiling and cheminformatics bioprospection of curcurbitacin I and momordin Ic fromJournal of enzyme inhibition and medicinal chemistry · 2025Article
- When Acarbose Overdose Turns Severe: Managing Hypoglycemia in an Uncommon Scenario.Clinical case reports · 2025Article
- Impact of Ultrasound-Treated Emulsion Gels on the Structure of Purees for Oropharyngeal Dysphagia.Molecules (Basel, Switzerland) · 2025Article
- Unlocking theMolecules (Basel, Switzerland) · 2025Article
- Borylated Five-Membered Ring Iminosugars: Synthesis, Spectroscopic Analysis, and Biological Evaluation for Glycosidase Inhibition and Anticancer Properties for Application in Boron Neutron Capture Therapy (BNCT)-Part 1.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Introduction of new quinolone-2-thio-acetamide-propane hydrazide-benzimidazole derivatives as new α-glucosidase and α-amylase inhibitors.Scientific reports · 2025Article
- In vivo anti-hyperglycemic activity and toxicity evaluation of two bis-coumarin derivative as potential α-glucosidase inhibitors.Journal of diabetes and metabolic disorders · 2025Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-prandial hyperglycemia still remains a problem in the management of type 2 diabetes mellitus. Of all available anti-diabetic drugs, α-glucosidase inhibitors seem to be the most effective in reducing post-prandial hyperglycemia. We conducted a review analyzing the clinical efficacy and safety of α-glucosidase inhibitors, both alone and in combination with other anti-diabetic drugs, with respect to glycemic control, inflammation and atherosclerosis. α-Glucosidase inhibitors proved to be effective and safe both in monotherapy and as an add-on to other anti-diabetic drugs. Compared to miglitol and voglibose, acarbose seems to have some additive effects such as stabling carotid plaques, and reducing inflammation. Acarbose also proved to reverse impaired glucose tolerance to normal glucose tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.